This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.
Hello, hello. Today we talk about whether the AI overlords will commandeer cancer research (on top of everything else in this world), WuXi is looking to sell some of its operations, ostensibly because of the BIOSECURE Act, and more.
The need-to-know this morning
-
Italian pharma company Recordati said it will buy from Sanofi the global rights to an approved drug to treat cold agglutinin disease, a rare autoimmune disorder, for $825 million.
Will AI replace principal investigators in cancer?
OpenAI co-founder Sam Altman claims that, one day, artificial intelligence could upend cancer research by replacing the principal investigator. But many scientists, including machine learning biologist Shantanu Singh of the Broad Institute, think AI lacks the ingenuity of a human scientist — and won’t be curing cancer any time soon.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
